about
HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC).Thrombocytopenia associated with c7E3 Fab (abciximab).Pancytopenia due to iron deficiency worsened by iron infusion: a case report.Hemodynamic collapse following bilateral knee arthroplasty: a mysterious case.Small lymphocytic lymphoma in a patient with CREST syndrome.Treatment options for relapsed small-cell lung cancer.Lung cancer in women: role of estrogensTargeting the EGFR signaling pathway in cancer therapy.Endothelium and the lipid metabolism: the current understanding.Myeloproliferative syndromes and the associated risk of coronary artery disease.Clinical course of lung cancer in patients with chronic kidney disease.Hormone replacement therapy is associated with decreased survival in women with lung cancer.Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: potential role in therapy.Profile of vismodegib and its potential in the treatment of advanced basal cell carcinomaIodine-refractory thyroid carcinoma.Smoking and microRNA dysregulation: a cancerous combination.Targeted anti-cancer therapy in the elderly.Predictive ability of Charlson comorbidity index on outcomes from lung cancer.Salivary duct carcinoma responding to trastuzumab-based therapy: case report and review of the literature.Human papilloma virus positive oropharyngeal squamous cell carcinoma: a growing epidemic.EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?Concurrent chemoradiotherapy in older adults with squamous cell head & neck cancer: Evidence and management.Epidermal growth factor receptor signaling in nonsmall cell lung cancer.Statins use and risk for brain metastasis from lung cancer.Early Stage Non-Small-Cell Lung Cancer in Octogenarian and Older Patients: A SEER Database Analysis.Advanced lung cancer in the older patient: is there a role for bevacizumab?Seliciclib in malignancies.Factors affecting the development of atrial fibrillation and atrial flutter (AF/AFL) following autologous hematopoietic SCT (auto-HSCT).Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma.Chromosomal anomalies in two coexistent myeloproliferative disorders.Angiosarcoma of the small intestine: a possible role for thalidomide?Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: a Veterans' Affairs Central Cancer Registry (VACCR) database analysis.Outcomes following surgical treatment compared to radiation for stage I NSCLC: a SEER database analysis.Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome.Risk-awareness of cutaneous malignancies among rural populations.Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations.Chemoradiotherapy for locally advanced squamous cell carcinoma of the oropharynx: Does completion of systemic therapy affect outcomes?Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.Cetuximab in hemodialysis: a case report.Clinical prognostic model for older patients with advanced non-small cell lung cancer
P50
Q24814451-3AFD76E9-40A7-4A54-9F60-DE05707E5CD5Q33341568-C8281910-D234-4021-B052-BC2EE14878FEQ33377712-E177635F-EE27-432E-98D0-301E2B7CD7FCQ33397309-247092B6-6955-4B20-97A3-B562BD9CE72BQ33397530-3DB1C660-8B6C-4519-A180-3710B6ED3C87Q34002194-28661F27-6E8B-4367-B1DB-C17F7A758845Q34083747-6AB24478-2CF5-4FF2-B66B-E38BE7AA6E5EQ34246558-5BE938B2-A91B-4B57-99B4-F947389AD3D7Q35093076-A78FAAFA-72A2-420A-8064-E2D644061B69Q35189578-FF840881-38C1-464F-8FF7-38A271E5D57EQ35785214-E04B2442-CA44-412C-AA82-1E4557F85480Q36325476-CC6D1795-996C-4D61-83D5-B1BACC787137Q36980219-E021B3FD-686A-45F6-A969-F94386454DD7Q37079100-9C1BA7DE-447D-41CB-89D8-F755ABA8B498Q37161155-EE1573AD-15FB-4B25-82A9-E60FD4940F9CQ37432727-8C416E36-BFAC-456C-8B86-ACF10BF457F0Q37769752-8DE44F3C-6187-4356-ADD0-E36D6F3AB422Q37827028-E4254A95-F527-4DE8-88E0-754A41B86E00Q38114366-5607DD1B-EB75-4EA5-942F-087371A08FCCQ38147683-EBF3CAEB-7FAE-420A-AE78-E222B399D99AQ38707112-6FBB0034-0868-4AB0-BFC9-89BE002B9645Q38754163-70A3BDCB-395C-4F48-92EE-6DE41851DA63Q39752055-5F179A5A-B1EC-4403-B619-C0CD528A913AQ39833666-10FFA046-C559-47FC-B87F-F350E194025EQ40149992-B2BE573F-5A0A-469C-8369-B6E8E225903AQ42355190-95B57D13-33BD-4C06-B789-56F2585A08D9Q43235605-60AA42A6-FEFA-45B7-83FF-304A42B1DD99Q43478731-B2434809-6B6D-46FE-AD3C-4F5DD59652B7Q44338521-11842544-4D22-4DE2-88F7-70D274BD9762Q44560524-6CBE24E3-B0F2-4760-B07A-0ED3B08F025EQ44723260-6C6032BE-667A-4640-A593-9CEBD8B51678Q45330765-FBA82D2B-D783-4809-9172-4A6D71310988Q46095093-052EF34F-ED9F-47DF-9AD3-68BCED61A0FAQ46568950-92DCFEA2-C232-458E-B5C2-92D13D1E4486Q47272765-D672BA38-A45D-42FC-BCD2-4AEDFDABDFDBQ47903473-05D15E57-19AB-4FCE-A7C3-93BA9A850C24Q47939737-001FEC32-3F89-4619-BA3F-239766F662AAQ51029459-1AE1985D-E491-4766-BF69-814525727CA9Q51770823-DFBC121A-68EB-4338-9506-B65AFC6825EDQ64115321-A916C6D1-8BBA-4BCA-8BE4-0F8A973F40C0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Apar Kishor Ganti
@ast
Apar Kishor Ganti
@en
Apar Kishor Ganti
@es
Apar Kishor Ganti
@nl
Apar Kishor Ganti
@sl
type
label
Apar Kishor Ganti
@ast
Apar Kishor Ganti
@en
Apar Kishor Ganti
@es
Apar Kishor Ganti
@nl
Apar Kishor Ganti
@sl
prefLabel
Apar Kishor Ganti
@ast
Apar Kishor Ganti
@en
Apar Kishor Ganti
@es
Apar Kishor Ganti
@nl
Apar Kishor Ganti
@sl
P1053
D-5498-2015
P106
P1153
7003922698
P31
P3829
P496
0000-0003-3724-2671